EYLEA Bayer Australia Ltd
Product name
EYLEA
Sponsor
Accepted date
Jan-2026
Active ingredients
Aflibercept
Proposed indication
EYLEA (aflibercept) is proposed to be used in adults to treat macular edema (swelling of the macula in the central region of the retina that affects sharp vision) caused by various types of retinal vein occlusion (blockage of veins draining blood from the retina).
Application type
C (new indication)
Publication date
Jan-2026